IgG3 Fc Overview
Molecule Name
Immunoglobulin G
Synonyms
Ig gamma-3 chain C region,IgG,IgG3
Drug Development Progress
Drugs in Clinical Trials8
Approved Drugs1
Highest Development StageApproved
Target Synonym
Immunoglobulin G
Background
Immunoglobulin G3 (IgG3) is a member of many immunoglobulin G developed and secreted by effective B cells. In wake of cutting by pepsin, IgG is divided into two F(ab)s with one antigen binding site and a high conserved Fc segment. The Fc segment bears a highly conserved N-glycosylation site. Ig gamma-3 chain C region (IgG3-Fc / IGHG3) contains two constant regions of IgG3 H chain (CH2, CH3).
IgG3 Fc Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ricefidase | KJ-103; KJ103 | Phase 3 Clinical | Shanghai Bao Pharmaceuticals Co Ltd | Anti-Glomerular Basement Membrane Disease; Guillain-Barre Syndrome; Rejection of renal transplantation | Details |
| AT-02 | AT-02 | Phase 2 Clinical | Attralus Inc | Amyloidosis; Immunoglobulin Light-chain Amyloidosis | Details |
| JZB-34 | AAFP; JZB-34 | Phase 1 Clinical | Shanghai Kexin Biotech Co Ltd | Hypersensitivity | Details |
| Emicizumab biosimilar (Jushi Biopharmaceutical) | SYS6053; SYS-6053 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Hemophilia A; Hemorrhage | Details |
| S-1117 | S-1117 | Phase 1 Clinical | Seismic Therapeutics Inc | Immune System Diseases | Details |
| BHV-1300 | BHV-1300 | Phase 1 Clinical | Biohaven Pharmaceuticals Inc | Arthritis, Rheumatoid; Graves Disease | Details |
| HNSA-5487 | HNSA 5487; HNSA-5487 | Phase 1 Clinical | Hansa Biopharma Ab | Autoimmune Diseases; Neoplasms | Details |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Imlifidase | Mac-1 | Approved | Hansamed Inc | Idefirix | EU | Rejection of renal transplantation | Hansa Biopharma Ab | 2020-08-25 | Guillain-Barre Syndrome; Kidney Diseases; Kidney Failure, Chronic; Purpura, Thrombotic Thrombocytopenic; Rejection of renal transplantation; Rejection of organ transplantation; Renal Insufficiency, Chronic | Details |